Alnylam Pharmaceuticals
ALNY
#663
Rank
ยฃ24.07 B
Marketcap
ยฃ186.65
Share price
-8.67%
Change (1 day)
37.14%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2024 (TTM): -ยฃ0.15 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are ยฃ2.09 Billion. In 2023 the company made an earning of -ยฃ0.25 Billion, an increase over its 2022 earnings that were of -ยฃ0.77 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) -ยฃ0.15 Billion-41.82%
2023 -ยฃ0.25 Billion-67.84%
2022 -ยฃ0.77 Billion36.93%
2021 -ยฃ0.57 Billion-8.04%
2020 -ยฃ0.62 Billion-15.66%
2019 -ยฃ0.73 Billion12.23%
2018 -ยฃ0.65 Billion62.91%
2017 -ยฃ0.4 Billion17.78%
2016 -ยฃ0.34 Billion43.44%
2015 -ยฃ0.24 Billion60.69%
2014 -ยฃ0.15 Billion98.2%
2013 -ยฃ73.65 Million
2011 -ยฃ43.44 Million27.48%
2010 -ยฃ34.08 Million-10.92%
2009 -ยฃ38.25 Million95.77%
2008 -ยฃ19.54 Million
2006 -ยฃ31.3 Million-9.13%
2005 -ยฃ34.45 Million34.74%
2004 -ยฃ25.57 Million36.79%
2003 -ยฃ18.69 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-ยฃ0.42 Billion 181.30%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ3.93 B-2,759.15%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ49.3 M-133.30%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ0.2 Billion 30.91%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ27.74 Million-81.27%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ10.08 B-6,912.96%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
ยฃ5.86 B-4,063.98%๐Ÿ‡ซ๐Ÿ‡ท France
ยฃ0.65 B-542.53%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel